✦ LIBER ✦

Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome

✍ Scribed by Roboz, G J; Giles, F J; List, A F; Cortes, J E; Carlin, R; Kowalski, M; Bilic, S; Masson, E; Rosamilia, M; Schuster, M W

Book ID: 110056732
Publisher: Nature Publishing Group
Year: 2006
Tongue: English
Weight: 120 KB
Volume: 20
Category: Article
ISSN: 0887-6924
DOI: 10.1038/sj.leu.2404213

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination decitabine, arsenic trioxide

Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: A phase I study

✍ John S. Welch; Jeffery M. Klco; Feng Gao; Elizabeth Procknow; Geoffery L. Uy; Ke 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 774 KB

Childhood immune thrombocytopenia (ITP) has a favorable outcome in most cases but severe bleeding may occur, mostly in children with very low platelet counts. Although first-line therapies are well defined, management of refractory ITP is not consensual. Vinblastine (VBL) is one second-line treatmen

A phase 1-2 study of a farnesyltransfera

A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome

✍ Elias Jabbour; Hagop Kantarjian; Farhad Ravandi; Guillermo Garcia-Manero; Zeev E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB 👁 1 views

## Abstract ## BACKGROUND: The authors conducted a phase 1/2 study of tipifarnib in combination with idarubicin and cytarabine (IA) in 95 patients with previously untreated acute myeloid leukemia (AML) or high‐risk myelodysplastic syndrome. ## METHODS: Induction consisted of idarubicin 12 mg/m^2